CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam ...

"This launch represents a major expansion of our professional learning portfolio, enabling us to provide even more impactful ...

CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of ...

At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...

UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...

Sleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease.

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

Prazer Therapeutics raises $20M Series B with JJDC's first South Korean investment; Carisma cuts to 6 staff; Cerevance's Parkinson's trial fails; FDA updates for Oncopeptides, Bavarian Nordic ...

This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...